Cellular prion protein (PrPC) has a high-affinity Aβ oligomers binding site and many lines of evidences delineate a signalling pathway involving Aβ complexation with PrPC to neuronal impairment in Alzheimer’s disease (AD)1. Treatment with a PrPC antibody against the Aβ oligomer binding site prevents the inhibition of long-term potentiation and reverses cognitive deficits in AD transgenic mice2. This project aims to develop a high-throughput screen assay by using HEK-293 cell line, which endogenously express PrPC, to identify new small molecules which can inhibit the PrPC-Aβ1-42 oligomers binding.
A novel cell-based assay to screen compounds which disrupts PrPC-Aβ1-42 oligomers interaction
Ghafir El Idrissi Imane
;Colabufo Nicola Antonio
;
2017-01-01
Abstract
Cellular prion protein (PrPC) has a high-affinity Aβ oligomers binding site and many lines of evidences delineate a signalling pathway involving Aβ complexation with PrPC to neuronal impairment in Alzheimer’s disease (AD)1. Treatment with a PrPC antibody against the Aβ oligomer binding site prevents the inhibition of long-term potentiation and reverses cognitive deficits in AD transgenic mice2. This project aims to develop a high-throughput screen assay by using HEK-293 cell line, which endogenously express PrPC, to identify new small molecules which can inhibit the PrPC-Aβ1-42 oligomers binding.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
